FGF21 and metabolic dysfunction-associated steatohepatitis: Administration of the FGF21 analogue pegbelfermin in humans with NASH causes at least a 30% relative reduction in hepatic fat content assessed in magnetic resonance imaging-proton density fat fraction in over half of the patients and a significant reduction of serum triglyceride levels (23).